A Phase 4 interventional study of Recombinant human growth hormone in Achondroplasia, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 2 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 4, Interventional, and Treatment
To Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children with Achondroplasia
47 studies on the registry are indexed under Achondroplasia; 14 are open to participants now.
This study's enrollment of 39 is below the median of 73 across 28 interventional studies indexed under Achondroplasia.
Browse Achondroplasia studies →Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 108 studies on the registry; 47 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria:
Recombinant human growth hormone Injection (15IU/5mg/3ml/bottle)；0.05 mg/kg/d by subcutaneous injection for 52 weeks
Drug: Recombinant human growth hormone
Recombinant human growth hormone (15IU/5mg/3ml/bottle)，0.05 mg/kg/d by subcutaneous injection for 52 weeks
Change From Baseline in Annualized Height Velocity (AHV) at Week 52
The change in AHV after 52 weeks treatment
Time frame: week 52
Change From Baseline in AHV
Change in AHV at week, week 13, week 26, week 39
Time frame: week 4, week 13, week 26, week 39
Change From Baseline in Height Standard Deviation Score (Ht SDS)
Change From Baseline in Ht SDS at week 4, week 13, week 26, week 39, week 52
Time frame: week 4, week 13, week 26, week 39, week 52
Change From Baseline in BMI Standard Deviation Score (BMI SDS)
Change From Baseline in BMI SDS at week 4, week 13, week 26, week 39, week 52
Time frame: week 4, week 13, week 26, week 39, week 52
Change From Baseline in Sitting Height/Leg Length ratio Standard Deviation Score (SH/LL SDS)
Change From Baseline in SH/LL SDS at week 4, week 13, week 26, week 39, week 52
Time frame: week 4, week 13, week 26, week 39, week 52
Change From Baseline in IGF-1 Standard Deviation Score (IGF -1 SDS)
Change From Baseline in IGF-1 SDS at week 4, week 13, week 26, week 39, week 52
Time frame: week 4, week 13, week 26, week 39, week 52
Change From Baseline in IGF-1/IGFBP-3 ratio
Change From Baseline in IGF-1/IGFBP-3 ratio at week 4, week 13, week 26, week 39, week 52
Time frame: week 4, week 13, week 26, week 39, week 52
Change From Baseline in Bone Age/Chronological Age ratio (BA/CA)
Change From Baseline in BA/CA at week 52
Time frame: week 52
Change From Baseline in Metabolism-related Proteins
Change From Baseline in Serum Proteomics at week 13, week 26, week 52
Time frame: week 13, week 26, week 52
Plan to share: No — Drugs belong to the sponsor before they are put into clinical trials and the site is only a contract research organization; It is an industry practice that intellectual property rights belong to the sponsor.
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Changchun GeneScience Pharmaceutical Co., Ltd.